Mikhail Blagosklonny is an oncology professor at Roswell Park Cancer Institute in Buffalo, New York. The scientist is involved in various research programs, including studying different aspects of oncology and aging. His research centers on both molecular and cellular cells. Mikhail studies oncogenes, tumor suppressors, cell cycle, apoptosis, mitosis, signal transduction, and anticancer strategies. The institute uses the outcome of these studies to advance cancer therapies.
The researcher has a sound educational background. After graduating with his undergraduate degree, Mikhail joined the First Pavlov State Medical University of St. Petersburg to study internal medicine. Later, he enrolled in the same university for his doctorate in experimental medicine and cardiology. Mikhail’s sound educational background has been the major pushing factor behind his successful career. As soon as he earned his Ph.D., he was employed by the New York Medical College in Valhalla to serve as an associate professor of medicine. In this position, he advanced his knowledge on cancer therapies. This saw Ordway Research Institute appoint him as a senior scientist. In 2009, he joined Roswell Park Cancer Institute as an oncology professor. Since then, he has remained at the facility.
At the firm, Mikhail focuses on cancer and targeted cancer therapies. He is charged with the duty of establishing how these treatments protect healthy cells from damages while destroying cancer cells. He is also involved in studying the underlying mechanism of aging and testing various anti-aging drugs.
The scientist is mainly known for his hypothesis on rapamycin and aging. According to the hypothesis, Mikhail believes that TOR signaling plays a critical role in aging and cancer. This means that anti-cancer drugs such as rapamycin can be used to treat aging. Mikhail is the most passionate advocate of the drug, rapamycin. Analysis and studies about the drug are showing positive results.
Mikhail Blogosklonny is also a renowned author of over 300 peer-reviewed papers on oncology. These papers mainly record the results of his studies. Moreover, Mikhail is the editor-in-chief of several journals. They include Oncotarget, Cell Cycle, and Aging. He is Cancer Biology & Therapy’s associate editor. In addition, he sits on the editorial board of Cell Death & Differentiation. Mikhail’s effective editorials skills have seen the journals have a positive impact in the lives of many people. Follow Mikhail on LinkedIn.
Clay B. Siegell is the President and CEO of Seattle Genetics– a company that he co-founded in 1998. He is also the chairman of the board at the enterprise. Clay B. Siegell, Ph.D. is a scientist by training, and he emphasizes targeted cancer therapies. He created Seattle Genetics on the foundation of drug development practices, rigorous research, scientific innovation and a passion for assisting patients. Through his guidance, the company has been able to get to its present position as a pioneer in the development of antibody conjugates for cancer treatment.
Before Seattle Genetics, Siegell worked with National Cancer Institute and the National Institute of Health between 1988 and 1991. In 1991 he joined Bristol-Myers Squibb Pharmaceutical Research Institute where he worked until 1997. He is a member of the board at Alder BioPharmaceuticals- a privately-owned biotechnology company as well as Washington Biotechnology and Biomedical Association. He also sits on the Board of Governors at Fred Hutchinson Cancer Research Business Alliance. Clay B. Siegel Ph.D. has bachelor’s degree in Zoology from Maryland University. He received his Ph.D. in Genetics from the George Washington University.
His work at Seattle Genetics
Under the leadership of Dr.Siegell, Seattle Genetics has managed to build different antibody therapies to tackle the unmet medical requirements of cancer patients. The company’s first commercial product- ADCETRIS, got approved in August 2011. The company also has 3 phases of clinical trials called ECHELON-1, ECHELON-2, and ALCANZA.
In his statement at the 5th annual CHI Antibody-Drug Conjugates Conference, Siegell confirmed that to-date; ADCETRIS has been used to treat over 15000 lymphoma patients. He believes that this product can be the base of therapy for the CD30-expressing malignancies.
Other than ADCETRIS, the company is also advancing seven clinical-stage programs. Their leading programs, SGN-CD33A and SGN-CD19A have generated motivating data that has led to the expanded clinical programs.
Siegel has also put the company into several strategic collaborations with major biotechnology and pharmaceutical enterprises in oncology. He has guided the capital-raising activities of the company, acquiring over $675 million through private and public financing. Currently, Seattle Genetics technology empowers over 20 of the clinical development ADCs through both their collaborator and proprietary programs.
Dr. Paul Lammers, the Chief Executive Officer and President of Mirna categorically stated that the company is excited to appoint Dr. Siegall into their distinguished group of directors. His accomplishments in building a successful oncology company and broad pharmaceutical industry experience will be invaluable to the Mirna board and team.
Dr. Siegall said that he was pleased to join the Mirna Board of Directors and is looking forward to working with the board towards its programs for the patients in need. MicroRNA-based therapeutics is a thrilling area of thorough cancer research and Mirna is in a strong position with able product candidates.
Seattle Genetics was co-founded by Dr. Clay Siegall in 1998. Through his uncompromising leadership, the company has built an assorted pipeline of antibody-based therapies to tackle unmet medical needs of cancer patients. It has entered into several strategic collaborations with principle pharmaceutical companies and biotechnology in oncology.
Dr. Siegall has lead Seattle Genetics’ capital raising activities with huge success. He has secured in excess of six hundred and seventy-five million from private and public financings. He is also on the panel of a private biotechnology company called Alder BioPharmaceuticals. He spent time in National Institutes of Health from 1988 to 1991 and Bristol-Myers Squibb Pharmaceutical Research Institute from 1991 to 1997. He is a well renown author with more than seventy publications and holds a B.S. in Zoology from the University of Maryland and a Ph.D. in Genetics from George Washington University.
miRNAs are approximately twenty-five nucleotides long and upset gene expression by networking with messenger RNAs. MiRNAs are encoded in the humanoid genome and are utilised as natural regulators of the global gene expression. MiRNA appears to normalise the expression of hundreds of different genes.